baricitinib
suitabl
treatment
thank
ennio
faval
colleagu
correspond
regard
suggest
use
baricitinib
treatment
sever
acut
respiratori
syndrom
coronaviru
infect
also
appreci
recognit
inhibit
numbassoci
kinas
enzym
could
inde
benefici
prevent
viru
infect
via
inhibit
clathrinmedi
endocytosi
welcom
opportun
fulli
explain
possibl
use
baricitinib
current
pandem
inde
accept
use
inhibitor
treat
viral
diseas
might
appear
illog
given
antivir
effect
interferon
larg
mediat
jakstat
signal
pathway
howev
administr
pegylatedinterferon
benefici
antivir
effect
origin
hope
clinic
trial
interferon
yield
inconsist
result
pathogen
effect
interferon
observ
viral
infect
specul
earli
asymptomat
diseas
stage
diseas
requir
admitt
hospit
approxim
patient
coronaviru
diseas
abl
clear
viru
larg
endogen
antivir
mechan
almost
certainli
includ
interferon
therefor
recommend
baricitinib
jak
inhibitor
given
individu
howev
patient
moder
diseas
requir
hospit
care
peak
load
occur
within
approxim
day
symptom
onset
later
viral
titr
decreas
patient
hyperinflamm
caus
sever
phase
diseas
akin
socal
cytokin
storm
clinic
sever
phase
accompani
high
level
signal
includ
increas
level
interferon
signal
jakstat
pathway
microarray
studi
cameron
colleagu
author
intriguingli
show
patient
sever
acut
respiratori
syndrom
sar
discharg
hospit
low
interferon
interferon
signal
activ
wherea
hypoxaemia
die
interferon
interferon
signal
promin
anim
model
design
understand
tempor
profil
sar
middl
east
respiratori
syndrom
diseas
author
show
interferon
interferon
action
earli
diseas
benefici
damag
later
stage
find
suggest
hospit
care
requir
patient
pathogen
infect
jakstat
pathway
inhibit
might
potenti
strategi
current
outbreak
need
understand
patient
might
benefit
treatment
cytokin
inhibitor
whether
one
pattern
diseas
progress
exist
stratif
prognost
model
requir
addit
need
identifi
optimum
time
administ
cytokin
inhibitor
requir
identif
appropri
biomark
anecdot
experi
suggest
short
time
baricitinib
might
use
durat
dose
day
caus
reactiv
latent
infect
herp
virus
tuberculosi
other
await
result
investigatorl
prospect
studi
eg
numer
treatment
includ
baricitinib
individu
singlearm
natur
studi
data
might
difficult
interpret
caution
headlin
socal
cure
infect
individu
recov
also
suggest
system
administr
interferon
patient
treat
hospit
might
harm
explain
previou
studi
interferon
yield
inconsist
result
although
ongo
concern
regard
design
drug
use
multicountri
solidar
trial
includ
use
interferon
realiti
opinion
howev
valid
lend
credenc
evidencebas
view
optim
data
ultim
best
obtain
randomis
control
trial
pjr
employe
benevol
ai
js
editorinchief
oncogen
js
sat
number
scientif
advisori
board
includ
benevol
ai
consult
lansdown
partner
vitruvian
sit
board
director
bb
biotech
healthcar
trust
chair
xerion
healthcar
mc
declar
compet
interest
event
relat
outbreak
evolv
rapidli
make
initi
thought
avail
correspond
good
faith
assist
global
respons
earli
investig
suggest
requir
detail
work
analysi
reli
constitut
kind
medic
advic
recommend
peter
j
richardson
mario
corbellino
justin
steb
jsteb
imperialacuk
